Glu-Phe | 20556-22-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Glu-Phe
• 英文别名: glutamylphenylalanine；Glutamyl-phenylalanine；(4S)-4-amino-5-[[(1S)-1-carboxy-2-phenylethyl]amino]-5-oxopentanoic acid
• CAS: 20556-22-3
• 化学式: C₁₄H₁₈N₂O₅
• 分子量: 294.307
• InChiKey: XMBSYZWANAQXEV-QWRGUYRKSA-N

物化性质

• 熔点：
  206 °C (decomp)(Solv: water (7732-18-5))
• 沸点：
  623.6±55.0 °C(Predicted)
• 密度：
  1.332±0.06 g/cm3(Predicted)
• 物理描述：
  Solid

计算性质

• 辛醇/水分配系数(LogP)：
  -3
• 重原子数：
  21
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  130
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  Glu-Phe 在 soybean cotyledon N-terminal acidic amino acid-specific aminopeptidase 作用下， 生成 L-谷氨酸 、 L-苯丙氨酸
  参考文献：
  名称：

  Purification and Characterization of an N-Terminal Acidic Amino Acid-Specific Aminopeptidase from Soybean Cotyledons (Glycine max)

  摘要：

  通过硫酸铵分级和 Q-sepharose、Phenyl sepharose 和 Superdex 200 连续柱层析，从大豆子叶中分离出一种催化 Glu-Glu 高效水解的新型酶。该酶的表观分子量为 56 kDa分别通过 SDS-聚丙烯酰胺凝胶电泳和 Superdex 200 HR 10/30 柱层析得出 510 kDa 和 510 kDa。该酶对 Glu-p-硝基苯胺 (pNA) 和 Asp-pNA 具有高活性，而 Leu-pNA、Phe-pNA、Ala-pNA 和 Pro-pNA 不被水解。合成的二肽 Glu-Xxx 和 Asp-Xxx 被水解，但 Xxx-Glu 没有被水解。使用这种纯化酶消化富含 Glu 的寡肽嗜铬粒蛋白 A (Glu-Glu-Glu-Glu-Glu-Met-Ala-Val-Val-Pro-Gln-Gly-Leu-Phe-Arg-Gly-NH2)也被调查。谷氨酸残基从N末端一一被切割。这些观察结果表明该酶从 N 末端含酸性氨基酸的肽中去除谷氨酰或天冬氨酰残基。人们认为它是一种来自植物的 N 末端酸性氨基酸特异性氨肽酶。

  DOI：

  10.1271/bbb.90617
• 作为产物：
  描述：

  L-苯基丙氨酸叔丁酯 在 氢溴酸 、 溶剂黄146 作用下， 生成 Glu-Phe
  参考文献：
  名称：

  Klieger,E.; Schroeder,E., Justus Liebigs Annalen der Chemie, 1963, vol. 661, p. 193 - 201

  摘要：

  DOI：

文献信息

• B LYMPHOCYTE SEPARATING MATERIAL AND BODY FLUID CLARIFYING MATERIAL
  申请人：TERUMO KABUSHIKI KAISHA

  公开号：EP0358758A1

  公开（公告）日：1990-03-21

  A B lymphocyte separating material, a method for separating B lymphocytes using same, and a separator are disclosed. The separating material comprises a water-insoluble solid substance having immobilized, directly or via a spacer, on the surface thereof an organically synthesized ligand having high affinity for immunoglobulin. A body fluid clarifying material and a body fluid clarifying apparatus using same are also disclosed. The material comprises a water-insoluble carrier having immobilized, directly or via a spacer, on the surface thereof a dipeptide or its derivative.

  本发明公开了一种 B 淋巴细胞分离材料、使用该材料分离 B 淋巴细胞的方法和分离器。该分离材料包括一种水不溶性固体物质，其表面直接或通过间隔物固定了一种有机合成配体，该配体对免疫球蛋白具有高亲和力。还公开了一种体液澄清材料和使用这种材料的体液澄清装置。该材料包括一种水不溶性载体，其表面直接或通过间隔物固定有二肽或其衍生物。
• Ingestibles containing substantially tasteless sweetness inhibitors as bitter taste reducers or substantially tasteless bitter inhibitors as sweet taste reducers
  申请人：BIORESEARCH, INC.

  公开号：EP0727149A2

  公开（公告）日：1996-08-21

  Sweetness inhibitors which are substantially tasteless have been found to be bitter taste inhibitors or blockers. Conversely, bitter taste inhibitors which are substantially tasteless have been found to be sweet taste inhibitors or blockers.

  已发现基本上无味的甜味抑制剂是苦味抑制剂或阻断剂。反之，基本无味的苦味抑制剂被发现是甜味抑制剂或阻断剂。
• Ingestible containing substantially tasteless sweetness inhibitors as bitter taste reducers or substantially tasteless bitter inhibitors as sweet taste reducers
  申请人：BIORESEARCH, INC.

  公开号：EP0728419A2

  公开（公告）日：1996-08-28

  Sweetness inhibitors which are substantially tasteless have been found to be bitter taste inhibitors or blockers. Conversely, bitter taste inhibitors which are substantially tasteless have been found to be sweet taste inhibitors or blockers.

  已发现基本上无味的甜味抑制剂是苦味抑制剂或阻断剂。反之，基本无味的苦味抑制剂被发现是甜味抑制剂或阻断剂。
• Biomarkers for fatty liver disease and methods using the same
  申请人：Metabolon Inc.

  公开号：EP2546649A2

  公开（公告）日：2013-01-16

  The present invention provides various biomarkers of fatty liver disease, including steatosis and steatohepatitis. The present invention also provides various methods of using the biomarkers, including methods for diagnosis of fatty liver disease, methods of determining predisposition to fatty liver disease, methods of monitoring progression/regression of fatty liver disease, methods of assessing efficacy of compositions for treating fatty liver disease, methods of screening compositions for activity in modulating biomarkers of fatty liver disease, methods of treating fatty liver disease, as well as other methods based on biomarkers of fatty liver disease.

  本发明提供了脂肪肝的各种生物标志物，包括脂肪变性和脂肪性肝炎。本发明还提供了使用这些生物标志物的各种方法，包括诊断脂肪肝的方法、确定脂肪肝易感性的方法、监测脂肪肝进展/恶化的方法、评估治疗脂肪肝组合物疗效的方法、筛选组合物调节脂肪肝生物标志物活性的方法、治疗脂肪肝的方法以及基于脂肪肝生物标志物的其他方法。
• Biomarkers for prostate cancer and methods using the same
  申请人：Metabolon Inc.

  公开号：EP2560006A2

  公开（公告）日：2013-02-20

  Methods for identifying and evaluating suites of biochemical and/or gene entities useful as biomarkers for early predication of prostate cancer, disease grading, target identification/validation, and monitoring of drug efficacy are provided. Also provided are suites of small molecule entities as biomarkers for prostate cancer

  本研究提供了鉴定和评估可用作前列腺癌早期预测、疾病分级、靶点鉴定/验证和药物疗效监测的生物标记物的生化和/或基因实体组的方法。此外，还提供了作为前列腺癌生物标记物的小分子实体套件。